IMMX Immix Biopharma Inc
4,107
$2.43
$0.08
(3.40%)
| Watchers | 4,107 |
| 52-Wk Low | $1.40 |
| 52-Wk High | $7.75 |
| Market Cap | $62.03M |
| Volume | 51,312.00 |
| 52-Wk High | $7.75 |
| 52-Wk Low | $1.40 |
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023InvestorPlace • about 1 month ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.
The post IMMX...
Share to Feed
Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 316,600 shares, a...
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) ( ImmixBio , Company , We or Us or IMMX ), a clinical-stage biopharmaceutical company trailblazing...
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness...
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
European Orphan Drug Designation ( ODD ) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the Company ), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease...
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ( Immix Biopharma , Company , We or Us , Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma (NASDAQ:IMMX Get Free Report) and Sage Therapeutics (NASDAQ:SAGE Get Free Report) are both small-cap medical companies, but which is the superior business? We will...